FAGR Fagron SA

Continued strong third quarter performance with 11% topline growth to €191 million

Continued strong third quarter performance with 11% topline growth to €191 million

Regulated information - inside information

Nazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET

Continued strong third quarter performance with 11% topline growth to €191 million

Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2023.

Key Highlights

  • Solid revenue growth continues with 10.6% reported growth (13.9% at CER) and 10.2% organic growth (13.4% at CER) to €191.4 million
  • Sustained strong performance in North America and solid recovery of Latin America; EMEA reflects completion of pricing pass through
  • Roll out of global operational excellence initiatives continues
  • Signing of Parma Produkt acquisition provides entry into attractive Hungarian compounding market
  • Science Based Targets initiative (SBTi) has approved our near-term science-based emission reduction target
  • FY 2023 revenue between €750-€770 million; improvement in profitability YoY

Rafael Padilla, CEO of Fagron:

“Our performance through the third quarter reflects the solidity of our diversified and defensive business model in a macro-economic environment that remains dynamic. Our results were driven by further enhancements to our commercial approach, reaping benefits of operational excellence initiatives, as well as excellent execution across our businesses. Organic revenue growth picked up pace this quarter, supported by all our regions, with North America delivering the highest organic growth in its history. This was driven by outstanding performances at both FSS and Anazao, as underlying demand for outsourcing compounding services remains strong. In EMEA, we saw revenue growth softening for the quarter following the completion of the pricing pass-through exercise in the first half of the year. Latin America continued its upward trajectory, supported by our focus on driving operational efficiencies and innovation.

We are also pleased to announce the signing of the Parma Produkt acquisition, which enables access to the attractive Hungarian market in line with our strategic plan to further diversify our EMEA footprint. We remain committed to consolidating the market and are assessing market opportunities across all our regions in line with our disciplined acquisition strategy.

Overall, we remain confident about our prospects and reiterate our midterm guidance. For FY 2023 we expect revenue between €750 million and €770 million and reiterate the expected profitability increase YoY.”

Please open the link below for the full press release:

Attachment



EN
12/10/2023

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Free Trial
FAGR FAGRON SA

Fagron NV: 1 director

Five Directors at Fagron NV bought/sold 189,367 shares at between 16.230EUR and 20.506EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

6h / 40m 6h / 40m 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron shareholders approve all voting items AGM

Fagron shareholders approve all voting items AGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET Fagron shareholders approve all voting items AGM Fagron, the leading global player in pharmaceutical compounding, held its annual general shareholders meeting today, where all the voting items were approved. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.35 per share for the fiscal year 2024, the remuneration policy and the appointment of the statutory auditor fo...

May 12, 2025 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering ...

Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 12 mei 2025 – 19:00u CET Aandeelhouders Fagron keuren alle agendapunten van de jaarvergadering goed Fagron, de toonaangevende mondiale speler in farmaceutische bereidingen, hield vandaag haar jaarlijkse algemene vergadering van aandeelhouders, waarbij alle ingediende voorstellen werden goedgekeurd. BesluitenDe jaarvergadering heeft onder andere Fagron’s jaarrekening en het dividendvoorstel van €0,35 per aandeel over het boekjaar 2024, het remunera...

May 12, 2025 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
EURN EURONAV NV
AGS AGEAS SA/NV
FAGR FAGRON SA
GREEN GREENYARD NV
SEQUA SEQUANA MEDICAL
04/14/25 April 14, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron Capital Markets Day feedback

Yesterday, Fagron hosted a Capital Markets Day where it laid out its strategic priorities for 2030. We see the updated Compounding for Growth strategy as a natural extension of the successful current trajectory. Financial targets are set for HSD-LDD organic CER revenue growth, a 21.0% REBITDA margin by 2027 progressively increasing thereafter to 2030, =70% operating cash conversion, =50% FCF conversion and 3.5% maintenance capex. Management continues to expect solid organic growth across all reg...

04/11/25 April 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch